Suchergebnisse - "Lanzilli, Giulia"

PubPharm (40)

1

Elimination of Egfr-Overexpressing Cancer Cells by CD32 Chimeric Receptor T Cells in Combination with Cetuximab or Panitumumab

enthalten in: bioRxiv.org | 2023

von Caratelli, S. | Arriga, R. | Sconocchia, T. | +13

2

Antibody-Independent Antitumor Effects of Cd32A-Chimeric Receptor T Cells: Implications for Breast Cancer Prognosis and Treatment

enthalten in: bioRxiv.org | 2023

von Sconocchia, G. | Lanzilli, G. | Cesarini, V. | +17

3

Direct CD32 T-cell cytotoxicity : implications for breast cancer prognosis and treatment

enthalten in: Life science alliance | 2022

von Sconocchia, G. | Lanzilli, G. | Cesarini, V. | +20

4

CD16-158-Valine Chimeric Receptor T Cells Overcome the Resistance of KRAS-mutated Colorectal Carcinoma Cells to Cetuximab

enthalten in: bioRxiv.org | 2020

von Arriga, R. | Caratelli, S. | Lanzilli, G. | +10

5

A possible interplay between HR-HPV and stemness in tumor development : an in vivo investigation of CD133 as a putative marker of cancer stem cell in HPV18-infected KB cell line

enthalten in: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica | 2020

von de Maria, S. | Santoro, A. | Fuggetta, M. | +12

6

CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab

enthalten in: International journal of cancer | 2020

von Arriga, R. | Caratelli, S. | Lanzilli, G. | +11

7

In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab

enthalten in: International journal of cancer | 2020

von Caratelli, S. | Arriga, R. | Sconocchia, T. | +13

8

A possible interplay between HR‐HPV and stemness in tumor development : an in vivo investigation of CD133 as a putative marker of cancer stem cell in HPV18‐infected KB cell line

enthalten in: APMIS | 2020

von Maria, S. | Santoro, A. | Fuggetta, M. | +12

9

In vitro elimination of epidermal growth factor receptor‐overexpressing cancer cells by CD32A‐chimeric receptor T cells in combination with cetuximab or panitumumab

enthalten in: International Journal of Cancer | 2020

von Caratelli, S. | Arriga, R. | Sconocchia, T. | +13

10

CD16‐158‐valine chimeric receptor T cells overcome the resistance of KRAS‐mutated colorectal carcinoma cells to cetuximab

enthalten in: International Journal of Cancer | 2020

von Arriga, R. | Caratelli, S. | Lanzilli, G. | +11